Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
Name:
document(1).pdf
Size:
889.0Kb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
Warwick Clinical Trials Unit, University of Warwick, CoventryIssue Date
2018-04-05
Metadata
Show full item recordAbstract
Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost.Citation
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. 2018, 18(1): 391 BMC CancerJournal
BMC CancerDOI
10.1186/s12885-018-4307-8PubMed ID
29621991Type
ArticleLanguage
enISSN
1471-2407ae974a485f413a2113503eed53cd6c53
10.1186/s12885-018-4307-8